BLMH/Bleomycin Hydrolase Antibody (760239) [Alexa Fluor® 405]

• Applications: WB, IHC, KO
• Clone: 760239
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 405

BLMH/Bleomycin Hydrolase Antibody (760239) [Alexa Fluor® 405] Summary

• Immunogen: E. coli-derived recombinant human BLMH/Bleomycin Hydrolase
  Ser2-Glu455
  Accession # Q13867
• Specificity: Detects human BLMH/Bleomycin Hydrolase in direct ELISAs. It detects human, mouse and rat BLMH/Bleomycin Hydrolase in Western Blots.
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

Bleomycin Hydrolase (BLMH) is a cysteine peptidase of the papain superfamily. It is named for its ability to hydrolyze the antitumor agent bleomycin and inactivate it (1). It has a papain-like catalytic triad (Cys-His-Asp) with optimum activity at neutral pH. In mammals it is expressed ubiquitously in all types of tissues and its expression is up‑regulated in many tumors. It is present in the cytoplasm as homohexameric protein of approximately 300 kDa. In addition to its aminopeptidase activity, it has homocysteine-thiolactonase activity. BLMH inactivates bleomycin, a glycopeptide anticancer agent, by deaminating it (2). BLMH has been suggested to play a role in the generation of MHC class I-presented peptides (3, 4). Diminished BLMH activity may contribute to the pathology of Alzheimer’s disease (AD) (5, 6). It is inhibited by cysteine protease inhibitors such as N-ethylmaleimide, iodoacetamide, para-hydroxymercuribenzoate, and E‑64.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.